OncoOne: targeting oxidized MIF for solid tumors

Led by Shire vets, the Austrian biotech is taking aim at a highly selective tumor antigen the biotech left behind

A trio of Shire veterans launched OncoOne on Wednesday with a €13 million series A round and a batch of biologics against oxidized MIF, a highly selective tumor antigen that was abandoned by the pharma when it shifted away from oncology R&D.

While the unmodified form of MIF, a well-known cytokine, is distributed throughout healthy tissues, the oxidized form is highly tumor cell-specific.

“During tumorigenesis,

Read the full 638 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE